Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn et al. Nov 03, 2025 pp. 2173-2173 10.1182/blood-2025-2173

Abstract Loss-of-function studies (LOF) have historically been the main functional approach to identify and study genes which drive the biol...

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

Kelly Schoenbeck, Joan Clements, Karen Demairo et al. Nov 03, 2025 pp. 6388-6388 10.1182/blood-2025-6388

Abstract INTRODUCTION: While TKIs significantly extend survival in CML, their adverse events (AEs) may lead to treatment discontinuation and...

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Gianluca Asti, Mattia Delleani, Patricia Apellaniz et al. Nov 03, 2025 pp. 4350-4350 10.1182/blood-2025-4350

Abstract Background: Access to large, diverse, and high-quality datasets is essential for advancing research in rare hematological diseases...

Tumor-specific risk of acute kidney injury: A multi-cancer comparison across matched real-world cohorts

Syed Pasha, Rakahn Haddadin, Pierre Khoury et al. Nov 03, 2025 pp. 3672-3672 10.1182/blood-2025-3672

Abstract Despite its frequency and prognostic significance, acute kidney injury (AKI) remains poorly stratified across cancer types, limitin...

Behavioral health and biophysical complexity as predictors of healthcare utilization in adults with sickle cell disease

Daniel Sop, Yue Zhang, Shirley Johnson et al. Nov 03, 2025 pp. 4364-4364 10.1182/blood-2025-4364

Abstract Background: Identifying predictors of high healthcare utilization in adults with Sickle Cell Disease (SCD) remains a clinical and o...

Experience with prolgolimab in the treatment of patients with relapsed and refractory classical Hodgkin lymphoma

Valeria Shpirko, Anastasia Semenova, Arman Arakelyan et al. Nov 03, 2025 pp. 7136-7136 10.1182/blood-2025-7136

Abstract Background: Modern treatment regimens for classical Hodgkin lymphoma (cHL) enable the cure of the majority of patients; however, re...

Unlocking the genetics of sickle cell disease

Mina Cintho Ozahata, Monike Oliveira, Claudia Maximo et al. Nov 03, 2025 pp. 2931-2931 10.1182/blood-2025-2931

Abstract Introduction Sickle cell disease (SCD) is associated with wide variability in clinical disease. Factors like β-globin genotype, co-...

The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance

Ting Du, Yuntong Liu, Minxing Wang et al. Nov 03, 2025 pp. 2148-2148 10.1182/blood-2025-2148

Abstract Background and Significance Therapeutic inhibition of the proteasomal catalytic activity of the 20S core particle (CP) by proteasom...

Disrupted DNA repair and oxidative stress responses underlie hematopoietic stem cell failure after spinal cord injury

Kyleigh Rodgers, Katherine Mifflin, Kristina Kigerl et al. Nov 03, 2025 pp. 3204-3204 10.1182/blood-2025-3204

Abstract Hematopoietic stem cells (HSCs) sustain lifelong blood and immune cell production through tightly regulated transitions between dor...

Transportation barriers and Medicaid's transportation service use in sickle cell disease: A mixed methods study in Wisconsin

Ashima Singh, M. Muska Nataliansyah, Mahua Dasgupta et al. Nov 03, 2025 pp. 2598-2598 10.1182/blood-2025-2598

Abstract Background: Individuals with sickle cell disease (SCD) often have socioeconomic barriers, limiting access to obtain care to manage...

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Mahasweta Gooptu, Monzr M. Al Malki, Stephanie Bo-Subait et al. Nov 03, 2025 pp. 4232-4232 10.1182/blood-2025-4232

Abstract Allogeneic hematopoietic cell transplantation (HCT) using an HLA mismatched unrelated donor (MMUD) with calcineurin inhibitor-based...

First in human prime edited autologous hematopoietic stem cell therapy for the treatment of p47phox CGD: Initial results of PRIME-0101

Elie Haddad, Haydar Frangoul, Donald Kohn et al. Nov 03, 2025 pp. 4319-4319 10.1182/blood-2025-4319

Abstract P47phox deficient phagocytic oxidase Chronic Granulomatous Disease (p47phox CGD) is an inherited immunodeficiency caused by mutatio...

Rare occurrence of liver failure secondary to sickle cell crisis and It's management

Alejandro Cruz Ponce, Nagapratap Ganta, Parul Jandir et al. Nov 03, 2025 pp. 6515-6515 10.1182/blood-2025-6515

Abstract Intro: Sickle cell disease (SCD) affects more than 8 million people worldwide and liver disease is an important...

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Tsewang Tashi, Hanneke Oude Elberink, Cem Akin et al. Nov 03, 2025 pp. 2024-2024 10.1182/blood-2025-2024

Abstract Introduction: Indolent systemic mastocytosis (ISM) is a clonal mast cell disease driven by the KIT D816V mutation in ~95% of cases...

Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas

Seda Tolu, Ted Piorczynski, Manuel Pazos et al. Nov 03, 2025 pp. 3558-3558 10.1182/blood-2025-3558

Abstract Introduction: Amplification of 9p24.1 (9p+) upregulates PDL-1/2 and JAK2, leading to an immune-privileged tumor microenvironment (TM...

Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy

Ho Ngai, Duncheng Wang, Yibin Chen et al. Nov 03, 2025 pp. 259-259 10.1182/blood-2025-259

Abstract Many myeloid malignancies are driven by acquisition of recurrent somatic mutations which increase cancer cell fitness and growth. T...

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short et al. Nov 03, 2025 pp. 1544-1544 10.1182/blood-2025-1544

Abstract Hyperglycemia is a well-recognized complication of induction chemotherapy in patients with B cell acute lymphoblastic leukemia (B-A...

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

Jieyu Xu, Haifeng Yu, Cong Li et al. Nov 03, 2025 pp. 7103-7103 10.1182/blood-2025-7103

Abstract IntroductionObinutuzumab combined with immunochemotherapy significantly improves outcomes in follicular lymphoma (FL) with high tum...

Clinical characterization of the rare G6PD pawnee variant: A five-patient case series

Nishi Harwani, Parul Rai, Clifford Takemoto Nov 03, 2025 pp. 4675-4675 10.1182/blood-2025-4675

Abstract Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common genetic condition, affecting an estimated 500 million people worldw...

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Maria Elisa Mancuso, Davide Matino, Dan Hart et al. Nov 03, 2025 pp. 302-302 10.1182/blood-2025-302

Abstract Background: NXT007 is a next-generation bispecific antibody, based on emicizumab, that mimics the cofactor function of activated fa...

Cumulative burden of myelodysplasia-related gene mutations is associated with poor leukemia-free survival in ELN-2022 favorable-risk AML

Lulu Zhang, Shuangwei Ying, Fang Fang et al. Nov 03, 2025 pp. 7025-7025 10.1182/blood-2025-7025

Abstract Background: The new category acute myeloid leukemia (AML) with myelodysplasia-related (MDS-R) gene is designated as “adverse-risk”...

Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS)

Michael Egan, Yogesh Chawla, Puja Dey et al. Nov 03, 2025 pp. 2149-2149 10.1182/blood-2025-2149

Abstract Altered Bone Marrow (BM) Plasma Amino Acid (AA) Composition Reflects Microenvironmental Remodeling in Patients with Multiple Myelom...

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson et al. Nov 03, 2025 pp. 2800-2800 10.1182/blood-2025-2800

Abstract Background: CAR T-cell therapy is an effective treatment for relapsed/refractory multiple myeloma (MM). CAR T-cell therapy is regar...

Smartphone app for noninvasive, at-home pediatric hemoglobin monitoring in sickle cell disease.

Rob Mannino, Kunjan Rana, Wilbur Lam et al. Nov 03, 2025 pp. 1158-1158 10.1182/blood-2025-1158

Abstract Anemia is a widespread health issue impacting more than 2 billion people worldwide. In sickle cell disease (SCD), which impacts mor...

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

Aryan Ayati, Xiaoliang Wang, Kanika Chandra et al. Nov 03, 2025 pp. 4528-4528 10.1182/blood-2025-4528

Abstract Background Next-generation covalent Bruton tyrosine kinase inhibitors (BTKi), including zanubrutinib (ZANU) and acalabrutinib (ACA)...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page